<DOC>
	<DOC>NCT00842244</DOC>
	<brief_summary>The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.</brief_summary>
	<brief_title>Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>confirmed diagnosis of stomach cancer advanced stomach cancer of stage IV adequate blood chemistry, blood counts and kidney function willing to participate to study requirements and sign an informed consent document prior chemotherapy for stomach cancer in its advanced stage excessive toxicities related to prior therapies pregnant or breastfeeding patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>